Cervical Disc Replacement — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cervical disc replacement (CDR), also called cervical total disc arthroplasty (TDA), is a spinal procedure that removes a degenerated or herniated cervical intervertebral disc and replaces it with an artificial disc prosthesis engineered to preserve segmental motion. This distinguishes CDR from the more traditional anterior cervical discectomy and fusion (ACDF), which permanently eliminates motion at the treated level. By maintaining biomechanical motion at the index level, CDR aims to reduce abnormal stress on adjacent discs, theoretically lowering the long-term risk of adjacent segment disease (ASD). FDA-approved devices include the Mobi-C (approved for single and two-level use), ProDisc-C, Bryan disc, Prestige LP, and PCM cervical disc. The procedure is performed through an anterior cervical approach similar to ACDF: a small transverse neck incision provides access to the disc space, followed by discectomy, neural decompression, careful end plate preparation to precise sizing, and prosthesis insertion and seating. Operative time is typically 1–2 hours. The choice of device depends on surgeon preference, patient anatomy, and disc space geometry. CDR is offered at high-volume spine surgery centers worldwide, with particularly strong programs in India, South Korea, Turkey, and Germany.

CDR is indicated for symptomatic cervical disc disease at one or two levels between C3 and C7. Primary indications include: (1) Cervical disc herniation with radiculopathy — arm pain, numbness, tingling, or weakness caused by nerve root compression from a herniated disc. (2) Cervical myelopathy from disc herniation — spinal cord compression producing gait disturbance, hand clumsiness, hyperreflexia, or Lhermitte's sign. (3) Symptomatic degenerative disc disease with radicular or myelopathic features that have failed at least 6 weeks of conservative management including physical therapy, anti-inflammatory medications, and cervical epidural steroid injections. (4) Cervical disc disease with objective neurological deficit — documented motor weakness or sensory deficit on examination correlating with imaging. (5) Discogenic neck and arm pain at motion-preserving levels where the patient has intact facet joints and good bone density. CDR is particularly advantageous over ACDF in younger, active patients who want to preserve neck mobility and minimize long-term risk of adjacent level degeneration. The FDA approved Mobi-C for two-level use specifically on the basis of superiority to two-level ACDF in the 84-month IDE trial.

Ideal candidates for CDR are skeletally mature adults (generally 21 years or older) with symptomatic single or two-level cervical disc disease (C3–C7) who have failed at least 6 weeks of conservative care. Key eligibility criteria include: intact or near-intact facet joints at the index level (confirmed by CT), no significant spondylosis or osteophyte bridging that would prevent prosthesis motion, preserved or minimal loss of disc height, no osteoporosis (DEXA scan T-score above −2.5), no prior cervical surgery at the index level, and no adjacent level fusion that would mandate a fused construct. Preoperative workup includes MRI with gadolinium (neural compression characterization), CT cervical spine (facet and bone quality assessment), plain X-rays with flexion-extension views (instability and alignment), and baseline neurological examination. Absolute contraindications: active spinal infection, allergy to implant materials (titanium, cobalt-chrome, or polyurethane components), severe osteoporosis, inflammatory arthropathy producing bridging syndesmophytes (e.g., ankylosing spondylitis, DISH), significant facet arthritis limiting motion preoperatively, segmental instability requiring fusion, and prior adjacent level fusion. Relative contraindications include morbid obesity and prior anterior cervical surgery creating adhesions. All candidates should be extensively counseled about the difference between CDR and ACDF including the small risk of requiring conversion to fusion.

Cervical disc replacement (CDR) uses a prosthetic intervertebral device to maintain motion at the operated segment:

• Surgical approach — anterior cervical discectomy: A 3–4 cm transverse incision in the right anterior neck provides access through the Smith-Robinson corridor. The diseased disc is removed, osteophytes decompressed, and the posterior longitudinal ligament opened to access the epidural space. The disc space is distracted to restore foraminal height, and the endplates are prepared to accept the implant.
• Implant design types: Ball-and-socket designs (Prestige LP, M6-C) — unconstrained motion in all planes; closest biomechanical analog to natural disc. Sliding core designs (Prodisc-C, Baguera-C) — semi-constrained with a central UHMWPE core that translates. Elastic core (M6-C) — visco-elastic design mimicking natural disc compliance and shock absorption through a polymer core and fiber annulus. Implants are composed of cobalt-chrome, titanium, or stainless-steel endplates with polyethylene (UHMWPE), ceramic, or pyrocarbon articulating surfaces. Titanium-coated plasma-sprayed endplates promote bone ingrowth without bone graft requirement.
• Multi-level CDR: FDA-approved at two adjacent levels (C3–C7). Three-level CDR is performed off-label with promising 5-year results. Multi-level CDR provides superior overall range of motion preservation compared to multi-level ACDF and theoretically reduces adjacent segment disease risk.
• Hybrid surgery: Combining CDR at one level with ACDF at an adjacent level — used when one level has anatomy unsuitable for arthroplasty (severe osteoporosis, facet arthropathy) while the adjacent level benefits from motion preservation.
• Single-level vs. two-level outcomes: RCT data from FDA Investigational Device Exemption (IDE) trials (Prestige, Mobi-C, ProDisc-C) consistently demonstrate CDR non-inferiority to ACDF at 2 years, with superior outcomes at 5–7 years for NDI, pain scores, and neurological status. Reoperation rates at the adjacent level are 50% lower in CDR vs. ACDF at 7-year follow-up.

Multiple FDA IDE randomized controlled trials and their long-term follow-up data establish CDR as at least equivalent to ACDF for single-level disease, and superior for two-level disease. The Mobi-C two-level FDA IDE trial (84-month follow-up): CDR demonstrated superior overall success versus two-level ACDF (69.4% vs 58.6%), better Neck Disability Index (NDI) improvement (54.9% vs 48.5%), and a significantly lower rate of adjacent segment reoperation (4.0% vs 11.7% ACDF). At the index level, CDR maintains an average of 8–10° of segmental motion throughout follow-up. Adjacent segment disease: CDR reduces radiographic adjacent segment disease by approximately 2.5-fold compared to ACDF at 5–7 year follow-up across multiple studies. Arm pain (VAS) reduction is comparable between CDR and ACDF (both achieve 60–75% improvement). Neurological success rates are equivalent. Return to desk work occurs at 4–6 weeks for most patients, equivalent to ACDF. Patient satisfaction at 7 years exceeds 80% for appropriately selected CDR patients. The motion-preservation benefit becomes more clinically meaningful over time, as adjacent segment degeneration in ACDF patients tends to progress after 5–7 years.

CDR shares risks common to all anterior cervical spine surgery but also carries unique device-related risks. Heterotopic ossification (HO) — pathological bone formation within or around the prosthesis reducing or eliminating motion — is the most common CDR-specific complication. Grade III–IV HO (bridging bone eliminating motion) occurs in 25–40% of cases depending on device type; the Bryan disc demonstrates the lowest HO rates among available devices, while some Asian populations show higher rates. HO does not always cause clinical problems but functionally converts CDR to a fusion outcome. Implant subsidence or migration occurs in less than 2% of cases. Dysphagia (difficulty swallowing) is common early (5–15%) due to retraction of the esophagus, similar rates to ACDF, and resolves in most cases; rare persistent dysphagia occurs (<2%). Dysphonia from recurrent laryngeal nerve stretch: <2%. Neurological injury including arm pain worsening is reported in less than 2% of cases; spinal cord injury is rare (<0.5%). Conversion to fusion is required in 1–3% of cases for implant failure, subsidence, or failure of decompression. Long-term implant wear debris — generation of polyurethane or metal particles — is a theoretical concern not yet proven to be clinically significant at 10-year follow-up. All patients should be counseled preoperatively that CDR may ultimately fail to preserve motion due to HO and that conversion to ACDF remains an option.

Recovery from CDR is typically faster than ACDF because no fusion is required:

• Hospital stay: Most single or two-level CDR procedures allow discharge on the same day or after one overnight stay. Patients are mobilized immediately with neck-specific precautions. No cervical collar required for CDR (unlike ACDF, which may need collar support during fusion consolidation).
• Activity progression: Light desk work resumes within 1–2 weeks. Driving permitted when safely able to turn the neck. Physical therapy for cervical range of motion and strengthening begins at 4–6 weeks. Return to non-contact physical activity at 6–8 weeks; contact sports at 3–6 months at surgeon's discretion.
• Radiographic monitoring: Lateral cervical X-rays (flexion-extension) at 6 weeks, 3 months, 6 months, 1 year, and 2 years confirm implant positioning, preservation of motion (>2° distinguishes a mobile from a fused arthroplasty), and absence of heterotopic ossification (HO). Grading of HO (McAfee classification I–IV) guides management — grade IV HO represents segment fusion, losing the motion-preserving advantage of CDR.
• Long-term surveillance: Annual clinical review at 5, 7, and 10 years recommended given the long-term implant durability data now available from FDA IDE trials. Neck pain, arm pain (VAS), and NDI documented at each review. MRI can be performed for adjacent segment evaluation; CDR implant artifacts are manageable with modern MRI sequences.

Cervical disc replacement costs vary significantly by country and reflect differences in implant costs, surgical fees, and facility overhead. In India, CDR at accredited hospitals such as Apollo, Fortis, or Medanta costs approximately $6,000–$14,000 all-inclusive (implant, surgeon, anesthesia, 2-night stay), representing savings of 70–85% versus US pricing. Thailand (Bumrungrad, Bangkok Hospital) charges $10,000–$20,000 with comparable implant quality to Western standards. Turkey ($8,000–$16,000) and South Korea ($12,000–$22,000) offer high-quality programs with experienced spine surgeons. In the United States, CDR ranges from $35,000–$80,000 depending on facility, with insurance coverage variable — many insurers still prefer ACDF coverage at single level despite FDA approval of CDR. United Kingdom NHS does not routinely fund CDR; private cost is £20,000–£45,000. Germany charges €20,000–€45,000 with BEK/statutory insurance typically covering approved devices. When seeking CDR abroad, patients should verify that the specific FDA/CE-approved implant (Mobi-C, Prestige LP, ProDisc-C, etc.) is being used at accredited JCI or equivalent facilities. Implant quality and surgeon experience are more important than cost alone given the 7+ year device longevity required.

The primary alternative to CDR is ACDF, with non-surgical options appropriate before any cervical surgery:

• Anterior cervical discectomy and fusion (ACDF): The traditional gold standard for cervical radiculopathy and myelopathy. A structural bone graft or PEEK cage is inserted after discectomy, with an anterior plate securing the construct. Achieves fusion in 90–95% of cases at one level. Disadvantage: eliminates segment motion, potentially accelerating degeneration at adjacent segments (adjacent segment disease affects 25% of patients at 10 years, with 10% requiring reoperation). ACDF remains preferred when CDR is contraindicated (severe facet arthropathy, osteoporosis, developmental canal stenosis, OPLL).
• Posterior cervical foraminotomy: A keyhole approach from the back removes bone and soft tissue compressing a cervical nerve root. Preserves disc and avoids hardware; suitable for lateral disc herniations and foraminal stenosis without central canal compromise or instability. No hardware-associated risks; motion fully preserved. Not applicable for central disc herniations causing myelopathy.
• Non-surgical management: Evidence supports an initial trial of conservative care for cervical radiculopathy — physical therapy (cervical traction, nerve mobilization, postural correction), anti-inflammatory medications, oral steroids for acute radiculopathy, and selective cervical nerve root injections for diagnostic and therapeutic purposes. 70–80% of cervical radiculopathy episodes resolve within 3–4 months with conservative care. Surgery is indicated for failure of conservative treatment, progressive neurological deficit, or myelopathy.